On October 9, METIS TECHBIO-P fell 6.37% in regular trading, with shares trading at 14.64港元 and turnover of 2217.51万港元.

The stock faced sustained selling pressure amid a broader retreat in the biotechnology sector, where sentiment has been dampened by shifting U.S. interest rate expectations that weigh on high-duration, pre-revenue biotech names. After a strong earlier run-up, Hong Kong biotech names, particularly AI-driven drug discovery companies, have entered a corrective phase.

Within the biotechnology sector, the overall performance was weak. Among individual stocks, INNOVENT BIO fell 2.86%, AKESO declined 1.32%, BEONE MEDICINES dropped 2.72%, 3SBIO was unchanged, and CANSINOBIO lost 2.73%.

METIS TECHBIO-P is engaged in artificial intelligence-driven nanomaterial innovation through its proprietary NanoForge platform, which integrates lipid libraries, AI foundation models, and high-throughput screening capabilities for advanced payload delivery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)